CD274 and melanoma: Subgroup analyses by CPS highlight the need for better predictors, particularly in the CPS < 1 group, as many patients with low CPS still derive benefit from ICI therapy [8, 19] and PD‐L1 expression does not seem to correlate with the disease control rate [4] Other studies have identified markers that can predict outcomes in patients treated with ICI, but most concentrate on solid tumors in general, melanoma, or non‐small‐cell lung cancer (NSCLC) [3, 20].